ENDOCRINOLOGY LABORATORY

Novel Gene Therapy Shows Promise in Treating Recurrent Respiratory Papillomatosis with 51% Complete Response Rate

4 months ago

A groundbreaking phase I/II trial of PRGN-2012 gene therapy demonstrated significant efficacy in treating recurrent respiratory papillomatosis (RRP), with 51% of patients achieving complete response. The treatment, which targets HPV-specific immunity, showed durable results extending beyond 12 months in most responders, potentially offering the first systemic treatment option for this rare chronic condition.

Tezepelumab Shows Promise in Phase III Trial for Chronic Rhinosinusitis with Nasal Polyps

6 months ago

• AstraZeneca's Tezspire (tezepelumab) significantly reduced nasal polyp size and congestion in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in the Phase III WAYPOINT trial. • The WAYPOINT trial evaluated tezepelumab versus placebo in adults with severe CRSwNP who remained symptomatic despite standard intranasal corticosteroid treatment. • Tezepelumab targets TSLP, a key epithelial cytokine, offering a potential new treatment option for CRSwNP patients and reducing the need for systemic corticosteroids or surgery. • The safety profile of tezepelumab in the WAYPOINT trial was consistent with its established profile, reinforcing its potential as a novel therapy for this debilitating condition.

Tezspire Meets Co-Primary Endpoints in Phase III WAYPOINT Trial for Chronic Rhinosinusitis with Nasal Polyps

6 months ago

• Tezspire (tezepelumab) demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size compared to placebo in the Phase III WAYPOINT trial. • The WAYPOINT trial also showed that Tezspire significantly reduced nasal congestion in adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP). • The safety and tolerability profile of Tezspire in the WAYPOINT trial was consistent with its known profile, reinforcing its potential as a treatment option. • Full results from the WAYPOINT trial will be presented to regulatory authorities and the scientific community at an upcoming medical meeting.

Tezspire Meets Primary Endpoints in WAYPOINT Trial for Chronic Rhinosinusitis with Nasal Polyps

6 months ago

• AstraZeneca and Amgen's Tezspire demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size compared to placebo in the Phase III WAYPOINT trial. • The trial evaluated Tezspire in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) who remained symptomatic despite standard intranasal corticosteroid treatment. • Tezspire's safety profile in the WAYPOINT trial was consistent with its known profile, reinforcing its potential as a novel treatment for CRSwNP. • Full results will be shared with regulatory authorities and the scientific community at an upcoming medical meeting, with Tezspire already approved for severe asthma in multiple countries.

Tezepelumab Shows Positive Phase III Results for Chronic Rhinosinusitis with Nasal Polyps

6 months ago

• AstraZeneca and Amgen's Tezspire (tezepelumab) significantly reduced nasal polyp size in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). • The WAYPOINT trial demonstrated a clinically meaningful reduction in nasal congestion compared to placebo in adults with severe CRSwNP. • The safety profile of tezepelumab in the WAYPOINT trial was consistent with its established profile, reinforcing its potential as a treatment option. • These results support tezepelumab's mechanism targeting TSLP, addressing multiple drivers of epithelial-driven inflammatory diseases.

Tezspire Meets Co-Primary Endpoints in Phase 3 Trial for Chronic Rhinosinusitis with Nasal Polyps

6 months ago

• The Phase 3 WAYPOINT trial demonstrated that Tezspire significantly reduced nasal polyp size in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). • Tezspire also significantly reduced nasal congestion compared to placebo in patients with CRSwNP, showing clinically meaningful improvements. • The safety and tolerability profile of Tezspire in the WAYPOINT trial were consistent with its known profile, reinforcing its potential as a treatment option. • These results support Tezspire's potential as a novel treatment for CRSwNP, addressing a significant unmet need for patients symptomatic despite standard care.

Tezspire Meets Primary Endpoints in Phase 3 WAYPOINT Trial for Chronic Rhinosinusitis with Nasal Polyps

6 months ago

• Tezspire (tezepelumab-ekko) demonstrated a statistically significant reduction in nasal polyp size compared to placebo in the Phase 3 WAYPOINT trial. • The trial also showed a clinically meaningful reduction in nasal congestion in patients treated with Tezspire versus those receiving placebo. • The safety and tolerability profile of Tezspire in the WAYPOINT trial was consistent with its established profile. • These results highlight Tezspire's potential as a novel treatment option for chronic rhinosinusitis with nasal polyps (CRSwNP).

Tezepelumab Shows Promise in Phase III WAYPOINT Trial for Chronic Rhinosinusitis with Nasal Polyps

6 months ago

• Tezepelumab met both co-primary endpoints in the WAYPOINT trial, significantly reducing nasal polyp size and congestion in CRSwNP patients. • The trial included patients symptomatic despite standard intranasal corticosteroid treatment, highlighting tezepelumab's potential for unmet needs. • The safety profile of tezepelumab in the WAYPOINT trial was consistent with its known profile, supporting its further development. • Full results will be shared with regulatory authorities and the scientific community, potentially expanding tezepelumab's approved indications.

Tezspire Meets Primary Endpoints in Phase III WAYPOINT Trial for Nasal Polyps

6 months ago

• AstraZeneca and Amgen's Tezspire demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size compared to placebo in the WAYPOINT trial. • The trial also showed a significant reduction in nasal congestion for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) treated with Tezspire. • Tezspire's safety profile in the WAYPOINT trial was consistent with its known profile, reinforcing its potential as a novel treatment option for CRSwNP. • These results support Tezspire's mechanism of action targeting TSLP, addressing multiple drivers of epithelial-driven inflammatory diseases.